Alemtuzumab CARE-MS I 5-year follow-up

@inproceedings{Havrdov2017AlemtuzumabCI,
  title={Alemtuzumab CARE-MS I 5-year follow-up},
  author={Eva Kubala Havrdov{\'a} and Douglas L. Arnold and Jeffrey A. Cohen and H. Hartung and Edward J. Fox and Gavin Giovannoni and Sven Schippling and Krzysztof W. Selmaj and Anthony Traboulsee and D. Alastair S. Compston and David H. Margolin and Karthinathan Thangavelu and Claudio Rodr{\'i}guez and Darlene Jody and Richard J. Hogan and Panos Xenopoulos and Michael A. Panzara and Alasdair John Coles},
  booktitle={Neurology},
  year={2017}
}
OBJECTIVE To evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients with active relapsing-remitting MS (RRMS) (CARE-MS I; NCT00530348). METHODS Alemtuzumab-treated patients received treatment courses at baseline and 12 months later; after the core study, they could enter an extension (NCT00930553) with as-needed alemtuzumab retreatment for relapse or MRI activity. Assessments included annualized relapse rate (ARR), 6-month confirmed disability worsening (CDW; ≥1-point… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 24 times. VIEW TWEETS